EcoDrugPlus

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSMPUG00000005883
Gene Symbol: SMO
2 Cross references
204 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Alpha

Ensembl ID : ENSMPUG00000016912
Gene Symbol: SCNN1A
2 Cross references
153 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Beta

Ensembl ID : ENSMPUG00000012101
Gene Symbol: SCNN1B
2 Cross references
151 Possible Orthologues:

Sodium Channel Epithelial 1 Subunit Gamma

Ensembl ID : ENSMPUG00000012095
Gene Symbol: SCNN1G
2 Cross references
155 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 1

Ensembl ID : ENSMPUG00000000687
Gene Symbol: SCN1A
2 Cross references
139 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSMPUG00000002519
Gene Symbol: SCN10A
2 Cross references
297 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSMPUG00000000672
Gene Symbol: SCN2A
2 Cross references
130 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSMPUG00000000669
Gene Symbol: SCN3A
2 Cross references
167 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSMPUG00000014784
Gene Symbol: SCN4A
4 Cross references
193 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 5

Ensembl ID : ENSMPUG00000002582
Gene Symbol: SCN5A
2 Cross references
94 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSMPUG00000000705
Gene Symbol: SCN7A
2 Cross references
86 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSMPUG00000007873
Gene Symbol: SCN8A
2 Cross references
274 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).